| abstract |
Disclosed are methods for diagnosing and treating diseases associated with TH2 inhibition, including but not limited to asthma. Possible response to treatment with a TH2 pathway inhibitor comprising determining whether a patient is eosinophilic inflammation positive (EIP) using an eosinophilic inflammation diagnostic assay (EIDA) A method for identifying a sex asthma patient or respiratory disease patient, wherein the EIP status indicates that the patient may respond to treatment with a TH2 pathway inhibitor. Patients to be treated with a TH2 pathway inhibitor are moderate to severe asthmatic patients who are not controlled with corticosteroids prior to treatment with a TH2 pathway inhibitor and are then treated with a TH2 pathway inhibitor (anti-IL-13 antibody). Treated with one, two, three or more controllers. [Selection figure] None |